Drug Search Results
More Filters [+]

Mosapride

Alternative Names: mosapride
Latest Update: 2024-04-26
Latest Update Note: PubMed Publication

Product Description

Hanmi Company Limited is developing Mosapride as a treatment for irritable bowel syndrome without diarrhea. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01505777)

Mechanisms of Action: 5-HT4 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | China | Dominican Republic | Egypt | India | Japan | Korea | Lebanon | Mexico | Pakistan | Philippines | Sri Lanka | Taiwan | Thailand | Ukraine | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Yabao Pharmaceutical Group
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mosapride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Gastroparesis|Type 2 Diabetes|Ileus|Irritable Bowel Syndrome|Constipation|Gastroesophageal Reflux|Esophagitis, Peptic

Phase 3: Ileus|Gastrointestinal Cancer

Phase 2: Irritable Bowel Syndrome|Diarrhea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2400088624

N/A

Recruiting

Constipation

2026-12-31

ChiCTR2400082798

N/A

Not yet recruiting

Dyspepsia

2024-12-01

COA.MURA2021/328

N/A

Unknown status

Ileus|Colorectal Cancer

2023-07-31

ChiCTR2100054269

N/A

Recruiting

Dyspepsia

2022-12-31

Recent News Events